Member Info for Adastra

Should bounce strongly and reinforce as US market kicks in later.

As a holder having topped up on the drops (As I highlighted on 30th Sept) I'm now buying again at my averaged price due to the current pullback. Very happy to consolidate my holding and faith in SN as it will be a major beneficiary as Covid recedes and elective surgery escalates. It's always been an £18+ share for 2022. Covid was the hiccough that let me buy into a secure future income at a ridiculously low price for a quality FTSE share.

But couldnt resist another dabble at £13.30 to drop my average down again. Happy holding.

Positive data on Covid suppression is music to SN so rerate now underway. Next hurdle £14 should be jumped in short order allowing £15 to be targeted by December.

SN taking a quick breather before next target assault on £14.....no brainer. Covid being driven down, operations being driven up.

Big drop takes out the t10 and t20 traders who were speculating before Nov 4th t/u. Should bounce quickly.

No need as it's a foregone that it will leapfrog forward imo before 3rd quarter results/update next Thursday......will comment again when my next marker falls at £14 (probably early in November). Kind regards...

As I said in my post 3165 on 11th Oct, having loaded up and exhaustedly highlighted this share at £12.49......I'd be back as it smashed through £13, here I am. Only three weeks later that marker has fallen. I expect £14 to follow quickly and then £15 and £16. Do the research and get on board, loads of upside beckons as should be confirmed in the t/u due on 4th Nov. Happy days.....back at £14.

Enough said.....done all the alerts to this that I can. Comment again as £13, £14, £15 and £16 markers fall but won't say 'told you so..DYOR

Underlooked Oversold and Undervalued......Boom!

This truly is an inflection point........ more than a few false indicators have fallen but reversal is imminent.....all the pointers are aligned. Roll on Nov 4th as it sprints to meet the update.

There is only so far the elastic here can be stretched before a feeding frenzy starts and institutions scramble to get on board. When the outlook of the big divi payers starts to falter, as it will, the underlying growth prospects and value inherent here will be blindingly obvious. Great opportunities don't come that often and this one is staring folk in the face, just do the research and draw your own conclusions.

Covid admission modelling for the NHS showed figures up to 12 times those currently being experienced and also 20% of patients on the waiting lists for hip and knee replacements are electing to go private. That's just in the UK as surgical procedures continue to ramp up. Given that the USA is the major market for S&N with the RoW increasing substantially, the November update should finally put this value erosion to bed.

I've shifted 60% of my pf into S&N as a hedge against any market correction since it should hold better and rerate faster given it's current oversold position. That isn't to say that it couldn't drop further with a substantial market drop but I'm comfortable with this exposure pending clarification of 3rd quarter results on Nov 4th. I take a medium term view, but it could easily sprint upwards to £16-18 on positive progress. Whatever happens the pent up demand is increasing weekly and the prospect of the superstar production plant coming on stream in Malaysia in the medium term adds confidence. It is a very specialist field in which SN operates with excellent provenance, massive consumer trust, v high barrier to entry and unique skills and IP.

S&N will be a major gainer next year as the huge backlog unwinds. Demand is escalating week on week with many patients opting to go private. It is certainly a recession-proof FTSE100 stock taking a contrarian Covid view. Time the market stopped looking so myopically and took a 6 month PLUS stance.

Easily achievable on volume, £16 is clearly the first hurdle in what I'm convinced will be a rapid ascent as sentiment has turned. The underlying strengths of S&N should then propel it through £17 where it should take a breather and form a new base as the positive (expected) trading update on Nov 4th sinks in and brokers upgrade on future prospects. Still plenty of scope to get on board. Early days of the rerate.

Yep. Hope all you guys loaded up when it bottomed in NYE and volume jumped. Was an excellent marker as I highlighted. Climb should accelerate now to the t/u in early November as traction in surgery progresses.

Big buys coming in this morning.......bid fodder???

On the way up - bounced strongly to $35.14 On NYSE with volume 200% above average......
Trajectory on course...£16 UK in the crosshairs!

$34.45 looks like it's bottomed on NYSE also....
Time will tell but there's a blue horizon coming into view for the first time in a month. October tomoro should see first signs of long awaited upswing....